Related Experiment Video

Updated: Jun 28, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

Hendrik Poeck1, Robert Besch, Cornelius Maihoefer

  • 1Institute of Clinical Chemistry and Pharmacology, University Hospital, University of Bonn, Bonn, Germany.

Nature Medicine
|November 4, 2008
PubMed

Insights

This study introduces a novel 3p-siRNA therapy targeting melanoma by activating the Rig-I pathway. This approach triggers anti-tumor immunity and apoptosis, effectively reducing lung metastases.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Tumor cells exhibit genetic and epigenetic plasticity, enabling evasion of single-targeted therapies.
  • Melanoma progression and metastasis pose significant therapeutic challenges due to treatment resistance.

Purpose of the Study:

  • To investigate the efficacy of Bcl2-specific short interfering RNA (siRNA) with 5'-triphosphate ends (3p-siRNA) as a dual-action therapeutic agent against melanoma.
  • To elucidate the mechanisms underlying 3p-siRNA-mediated anti-tumor activity, including innate immune activation and direct tumor cell apoptosis.

Main Methods:

  • Administration of 3p-siRNA targeting Bcl2 in a melanoma model.
  • Assessment of retinoic acid-induced protein I (Rig-I) activation and downstream signaling.
  • Evaluation of innate immune cell activation (dendritic cells, natural killer cells), interferon (IFN) production, and tumor cell apoptosis in vitro and in vivo.
  • Analysis of Bcl2 messenger RNA (mRNA) cleavage and Bcl-2 protein levels in tumor cells.

Main Results:

  • Recognition of 3p-siRNA by Rig-I activated innate immune cells and induced IFN expression and apoptosis in tumor cells.
  • Synergistic effect of Rig-I activation and Bcl2 silencing led to massive apoptosis in lung metastases.
  • Therapeutic efficacy was dependent on natural killer cells, IFN, and successful Bcl2 silencing, confirmed by rescue experiments and target validation.

Conclusions:

  • 3p-siRNA represents a single-molecule therapeutic strategy that simultaneously activates innate immunity and silences a key survival gene (Bcl2) in tumor cells.
  • This approach overcomes immune ignorance and addresses critical molecular events driving tumor cell survival, offering a promising avenue for melanoma treatment.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...